Photo by atikahakhtar from unsplash
We read with interest Molloy et al's letter describing a patient with recalcitrant nodular prurigo (NP) responding to tofacitinib.1 While we recognise the IL-31 and IL-4 mediated therapeutic potential of… Click to show full abstract
We read with interest Molloy et al's letter describing a patient with recalcitrant nodular prurigo (NP) responding to tofacitinib.1 While we recognise the IL-31 and IL-4 mediated therapeutic potential of tofacitinib to inhibit pruritus, our experience has been disappointing. We present three further cases that highlight the heterogeneity in the response of NP to tofacitinib.
Keywords:
recalcitrant nodular;
successful treatment;
nodular prurigo;
comment successful;
treatment recalcitrant
Journal Title: Clinical and Experimental Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical and Experimental Dermatology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!